Today I will be live-blogging the FDA's Cardiovascular and Renal Drugs Advisory Committee meeting to consider the supplemental new drug application (sNDA) for rivaroxaban (Xarelto, Johnson & Johnson) for use in patients with acute coronary syndrome (ACS) already taking dual antiplatelet therapy. Here is a link to the FDA briefing documents. And if you want to follow along from home you can also ...
Read More... [Source: - Posted by FreeAutoBlogger]